Physician profile
Peter Kim
NPI 1760898555
$1,458.86
in general payments reported to CMS, 2019-2025
19 companies · $59.53 in 2025
The $59.53 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $412 · 2022: $129 · 2023: $252 · 2024: $126 · 2025: $59.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $422 · Education: $14.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $422.49 |
| Education | $14.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $370.57 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $334.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $153.51 | 2019-2020 | |
| Amarin Pharma, INC. | $87.66 | 2019-2020 | |
| Lilly USA, LLC | $82.65 | 2019-2020 | |
| Pfizer INC. | $64.38 | 2020-2025 | |
| Astellas Pharma US INC | $62.66 | 2023-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $56.24 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $42.96 | 2019-2020 | |
| Glaxosmithkline, LLC. | $39.99 | 2019 | |
| Amgen INC. | $39.06 | 2019-2020 | |
| Abbott Laboratories | $31.88 | 2019-2024 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $17.21 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.66 | 2023 | Xifaxan |
| Upsher-Smith Laboratories LLC | $13.94 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $12.50 | 2020 | |
| Ironshore Pharmaceuticals INC. | $12.12 | 2019 | |
| Allergan, INC. | $11.75 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.